There are also preclinical efforts to assess the TGFβ inhibitor decorin, which has demonstrated a reduction in fibrosis and a nonsignificant increase in survival in RDEB mouse models (Cianfarani et al, 2019). Here, TGFB1 is linked to recessive dystrophic epidermolysis bullosa.